Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 325,258 |
|
|||||
| News | - | ||||||
| Day High | 4.725 | Low High |
|||||
| Day Low | 4.38 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| MaxCyte Inc | MXCT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.18 | -3.87% | 4.47 | 19:20:15 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.65 | 4.38 | 4.725 | 4.48 | 4.65 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,906 | 325,258 | $ 4.55 | $ 1,481,102 | - | 2.45 - 5.545 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:59:47 | 1 | $ 4.69 | USD |
MaxCyte Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 462.67M | 103.50M | - | 41.29M | -37.92M | -0.37 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
MaxCyte News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MXCT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.47 | 4.86 | 4.38 | 4.71 | 301,220 | 0.00 | 0.00% |
| 1 Month | 3.95 | 5.14 | 3.74 | 4.57 | 493,508 | 0.52 | 13.16% |
| 3 Months | 4.06 | 5.14 | 3.57 | 4.23 | 531,772 | 0.41 | 10.10% |
| 6 Months | 4.85 | 5.545 | 3.57 | 4.62 | 680,890 | -0.38 | -7.84% |
| 1 Year | 3.96 | 5.545 | 2.45 | 4.15 | 656,422 | 0.51 | 12.88% |
| 3 Years | 16.99 | 17.44 | 2.45 | 6.23 | 605,745 | -12.52 | -73.69% |
| 5 Years | 16.99 | 17.44 | 2.45 | 6.23 | 605,745 | -12.52 | -73.69% |
MaxCyte Description
| MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies. |
